NCT03758781View on ClinicalTrials.gov

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

February 21, 2021

Study Completion Date

August 11, 2021

Conditions
Metastatic CancerRecurrent CancerSolid TumorRenal Cell CarcinomaUrothelial CarcinomaNSCLCSquamous Cell CarcinomaNon-Small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

IRX 2

IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.

DRUG

Nivolumab

Nivolumab 240 mg will be given via IV infusion once every 2 weeks.

Trial Locations (1)

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03758781 - IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter